IL-33 exacerbates autoantibody-induced arthritis

Journal of Immunology

Volumn 184, Issue 5, 2010, Pages 2620-2626

  Xu, Damo ^a   Jiang, Hui Rong ^a,d   Li, Yubin ^a   Pushparaj, Peter N ^a   Kurowska Stolarska, Mariola ^a   Leung, Bernard P ^c   Mu, Rong ^a   Tay, Hwee Kee ^a   McKenzie, Andrew N J ^b   McInnes, Iain B ^a   Melendez, Alirio J ^a   Liew, Foo Y ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOKINE; GLUCOSE 6 PHOSPHATE ISOMERASE; INTERLEUKIN 33; INTERLEUKIN RECEPTOR; IL1RL1 PROTEIN, MOUSE; INTERLEUKIN 33, MOUSE; INTERLEUKIN DERIVATIVE; INTERLEUKIN-33, MOUSE;

ADAPTIVE IMMUNITY; ALPHA CHAIN; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; AUTOANTIBODY INDUCED ARTHRITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE SEVERITY; FIBROBLAST; IN VITRO STUDY; INNATE IMMUNITY; MAST CELL; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SYNOVIUM; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; DEGRANULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETICS; IMMUNOLOGY; JOINT; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; CELL DEGRANULATION; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE-6-PHOSPHATE ISOMERASE; INTERLEUKINS; JOINTS; MAST CELLS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN;

EID: 77951888994     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902685     Document Type: Article

References (47)

1. Janossy, G., G. Panayi, O. Duke, M. Bofill, L. W. Poulter, and G. Goldstein. 1981. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet 318: 839-842. (Pubitemid 11017556)
2. Feldmann, M., F. M. Brennan, and R. N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14: 397-440.
3. McInnes, I. B., and G. Schett. 2007. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7: 429-442.
4. Edwards, J. C., L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D. R. Close, R. M. Stevens, and T. Shaw. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350: 2572-2581.
5. Emery, P., R. Fleischmann, A. Filipowicz-Sosnowska, J. Schechtman, L. Szczepanski, A. Kavanaugh, A. J. Racewicz, R. F. van Vollenhoven, N. F. Li, S. Agarwal, et al, and DANCER Study Group. 2006. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54: 1390-1400.
6. Leadbetter, E. A., I. R. Rifkin, A. M. Hohlbaum, B. C. Beaudette, M. J. Shlomchik, and A. Marshak-Rothstein. 2002. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416: 603-607.
7. Lee, D. M., D. S. Friend, M. F. Gurish, C. Benoist, D. Mathis, and M. B. Brenner. 2002. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 297: 1689-1692.
8. Edwards, J. C., and G. Cambridge. 2006. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6: 394-403.
9. Stuart, J. M., and F. J. Dixon. 1983. Serum transfer of collagen-induced arthritis in mice. J. Exp. Med. 158: 378-392.
10. Cook, A. D., M. J. Rowley, I. R. Mackay, A. Gough, and P. Emery. 1996. Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum. 39: 1720-1727.
11. Corr, M., and B. Crain. 2002. The role of FcγR signaling in the K/B x N serum transfer model of arthritis. J. Immunol. 169: 6604-6609.
12. Nandakumar, K. S., and R. Holmdahl. 2006. Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res. Ther. 8: 223.
13. Galli, S. J., M. Grimbaldeston, and M. Tsai. 2008. Immunomodulatory mast cells: negative, aswell as positive, regulators of immunity. Nat. Rev. Immunol. 8: 478-486.
14. Sayed, B. A., A. Christy, M. R. Quirion, and M. A. Brown. 2008. The master switch: the role of mast cells in autoimmunity and tolerance. Annu. Rev. Immunol. 26: 705-739.
15. Bromley, M., W. D. Fisher, and D. E. Woolley. 1984. Mast cells at sites of cartilage erosion in the rheumatoid joint. Ann. Rheum. Dis. 43: 76-79.
16. Tetlow, L. C., and D. E. Woolley. 1995. Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies. Ann. Rheum. Dis. 54: 896-903.
17. Ruschpler, P., P. Lorenz, W. Eichler, D. Koczan, C. Hänel, R. Scholz, C. Melzer, H. J. Thiesen, and P. Stiehl. 2003. High CXCR3 expression in synovial mast cells associated with CXCL9 and CXCL10 expression in inflammatory synovial tissues of patients with rheumatoid arthritis. Arthritis Res. Ther. 5: R241-R252.
18. Eklund, K. K. 2007. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol. Rev. 217: 38-52.
19. Schmitz, J., A. Owyang, E. Oldham, Y. Song, E. Murphy, T. K. McClanahan, G. Zurawski, M. Moshrefi, J. Qin, X. Li, et al. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490.
20. Carriere, V., L. Roussel, N. Ortega, D. A. Lacorre, L. Americh, L. Aguilar, G. Bouche, and J. P. Girard. 2007. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. USA 104: 282-287.
21. Moussion, C., N. Ortega, and J. P. Girard. 2008. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 3: e3331.
22. Cayrol, C., and J. P. Girard. 2009. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc. Natl. Acad. Sci. USA 106: 9021-9026.
23. Lüthi, A. U., S. P. Cullen, E. A. McNeela, P. J. Duriez, I. S. Afonina, C. Sheridan, G. Brumatti, R. C. Taylor, K. Kersse, P. Vandenabeele, et al. 2009. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 31: 84-98.
24. Ali, S., M. Huber, C. Kollewe, S. C. Bischoff, W. Falk, and M. U. Martin. 2007. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc. Natl. Acad. Sci. USA 104: 18660-18665.
25. Chackerian, A. A., E. R. Oldham, E. E. Murphy, J. Schmitz, S. Pflanz, and R. A. Kastelein. 2007. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J. Immunol. 179: 2551-2555.
26. Xu, D., W. L. Chan, B. P. Leung, F. Huang, R. Wheeler, D. Piedrafita, J. H. Robinson, and F. Y. Liew. 1998. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J. Exp. Med. 187: 787-794.
27. Sanada, S., D. Hakuno, L. J. Higgins, E. R. Schreiter, A. N. McKenzie, and R. T. Lee. 2007. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117: 1538-1549.
28. + T cells and promotes allergic-induced airway inflammation independent of IL-4. J. Immunol. 181: 4780-4790.
29. Smithgall, M. D., M. R. Comeau, B. R. Yoon, D. Kaufman, R. Armitage, and D. E. Smith. 2008. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int. Immunol. 20: 1019-1030.
30. Miller, A. M., D. Xu, D. L. Asquith, L. Denby, Y. Li, N. Sattar, A. H. Baker, I. B. McInnes, and F. Y. Liew. 2008. IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205: 339-346.
31. Verri, W. A., Jr., A. T. Guerrero, S. Y. Fukada, D. A. Valerio, T. M. Cunha, D. Xu, S. H. Ferreira, F. Y. Liew, and F. Q. Cunha. 2008. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc. Natl. Acad. Sci. USA 105: 2723-2728.
32. Leung, B. P., D. Xu, S. Culshaw, I. B. McInnes, and F. Y. Liew. 2004. A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J. Immunol. 173: 145-150.
33. Xu, D., H. R. Jiang, P. Kewin, Y. Li, R. Mu, A. R. Fraser, N. Pitman, M. Kurowska-Stolarska, A. N. McKenzie, I. B. McInnes, and F. Y. Liew. 2008. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl. Acad. Sci. USA 105: 10913-10918.
34. Palmer, G., D. Talabot-Ayer, C. Lamacchia, D. Toy, C. A. Seemayer, S. Viatte, A. Finckh, D. E. Smith, and C. Gabay. 2009. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum. 60: 738-749.
35. Brint, E. K., D. Xu, H. Liu, A. Dunne, A. N. McKenzie, L. A. O'Neill, and F. Y. Liew. 2004. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol. 5: 373-379.
36. Pushparaj, P. N., H.K. Tay, S. C. H'ng, N. Pitman, D. Xu, A. McKenzie, F.Y. Liew, and A. J. Melendez. 2009. The cytokine interleukin-33 mediates anaphylactic shock. Proc. Natl. Acad. Sci. USA 106: 9773-9778.
37. Pushparaj, P. N., J. Manikandan, H. K. Tay, S. C. H'ng, S. D. Kumar, J. Pfeilschifter, A. Huwiler, and A. J. Melendez. 2009. Sphingosine kinase 1 is pivotal for FcεRI-mediated mast cell signaling and functional responses in vitro and in vivo. J. Immunol. 183: 221-227.
38. Ji, H., A. Pettit, K. Ohmura, A. Ortiz-Lopez, V. Duchatelle, C. Degott, E. Gravallese, D. Mathis, and C. Benoist. 2002. Critical roles for interleukin 1 and tumor necrosis factor a in antibody-induced arthritis. J. Exp. Med. 196: 77-85.
39. Nigrovic, P. A., B. A. Binstadt, P. A. Monach, A. Johnsen, M. Gurish, Y. Iwakura, C. Benoist, D. Mathis, and D. M. Lee. 2007. Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc. Natl. Acad. Sci. USA 104: 2325-2330.
40. Moritz, D. R., H. R. Rodewald, J. Gheyselinck, and R. Klemenz. 1998. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J. Immunol. 161: 4866-4874.
41. Allakhverdi, Z., D. E. Smith, M. R. Comeau, and G. Delespesse. 2007. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J. Immunol. 179: 2051-2054.
42. Iikura, M., H. Suto, N. Kajiwara, K. Oboki, T. Ohno, Y. Okayama, H. Saito, S. J. Galli, and S. Nakae. 2007. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab. Invest. 87: 971-978.
43. Moulin, D., O. Donzé, D. Talabot-Ayer, F. Mézin, G. Palmer, and C. Gabay. 2007. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 40: 216-225. (Pubitemid 350213434)
44. Chervenick, P. A., and D. R. Boggs. 1969. Decreased neutrophils and megakaryocytes in anemic mice of genotype W/W. J. Cell. Physiol. 73: 25-30.
45. W-sh mice does not impair antibody-mediated arthritis. J. Exp. Med. 204: 2797-2802.
46. Ji, H., K. Ohmura, U. Mahmood, D. M. Lee, F. M. Hofhuis, S. A. Boackle, K. Takahashi, V. M. Holers, M. Walport, C. Gerard, et al. 2002. Arthritis critically dependent on innate immune system players. Immunity 16: 157-168.
47. Chen, M., B. K. Lam, Y. Kanaoka, P. A. Nigrovic, L. P. Audoly, K. F. Austen, and D. M. Lee. 2006. Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J. Exp. Med. 203: 837-842.